<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30386243</article-id>
<article-id pub-id-type="pmc">6198170</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2018.01182</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and Future Perspective</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>Kenji</given-names>
</name>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/73792/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff><institution>Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health</institution>, <addr-line>Chiba</addr-line>, <country>Japan</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Javier Egea, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, Spain</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Giustino Orlando, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy; Claudio Ferrante, Università degli Studi G. d’Annunzio Chieti e Pescara, Italy</p>
</fn>
<corresp id="c001">*Correspondence: Kenji Hashimoto, <email>hashimoto@faculty.chiba-u.jp</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>10</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<volume>9</volume>
<elocation-id>1182</elocation-id>
<history>
<date date-type="received">
<day>13</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>28</day>
<month>9</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Hashimoto.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Hashimoto</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Depression is one of the most common mood disorders with a high rate of relapse. Accumulating evidence suggests that the transcription factor Kelch-like erythroid cell-derived protein with CNC homology (ECH)-associated protein 1 (Keap1)-Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) system plays a key role in inflammation which is involved in depression. Preclinical studies demonstrated that the protein expressions of Keap1 and Nrf2 in the prefrontal cortex (PFC), CA3 and dentate gyrus (DG) of hippocampus in mice with depression-like phenotype were lower than control mice. In the learned helplessness paradigm, the protein levels of Keap1 and Nrf2 in the PFC and DG of hippocampus from rats with depression-like phenotype were also lower than control and resilient rats. Furthermore, rodents with depression-like phenotype have higher levels of pro-inflammatory cytokines. Interestingly, <italic>Nrf2</italic> knock-out (KO) mice exhibit depression-like phenotype, and higher serum levels of pro-inflammatory cytokines compared with wild-type mice. Furthermore, <italic>Nrf2</italic> KO mice have lower expression of brain-derived neurotrophic factor (BDNF) in the PFC, and CA3 and DG of hippocampus compared to wild-type mice. 7,8-Dihydroxyflavone, a TrkB agonist, showed antidepressant effects in <italic>Nrf2</italic> KO mice, by stimulating BDNF-TrkB in the PFC, CA3, and DG. Pretreatment with sulforaphane, a naturally occurring Nrf2 activator, prevented depression-like phenotype in mice after inflammation, or chronic social defeat stress. Interestingly, dietary intake of 0.1% glucoraphanin (a precursor of sulforaphane) containing food during juvenile and adolescent stages of mice could prevent depression-like phenotype in adulthood after chronic social defeat stress. Moreover, the protein expressions of Keap1 and Nrf2 in the parietal cortex from major depressive disorder and bipolar disorder were lower than controls. These findings suggest that Keap1-Nrf2 system plays a key role in the stress resilience which is involved in the pathophysiology of mood disorders. It is, therefore, possible that dietary intake of cruciferous vegetables including glucoraphanin (or SFN) may prevent or minimize relapse from remission, induced by stress and/or inflammation in depressed patients. In the review, the author would like to discuss the role of Keap1-Nrf2 system in mood disorders.</p>
</abstract>
<kwd-group>
<kwd>brain-derived neurotrophic factor</kwd>
<kwd>glucoraphanin</kwd>
<kwd>keap1</kwd>
<kwd>Nrf2</kwd>
<kwd>nutrition</kwd>
<kwd>stress resilience</kwd>
<kwd>sulforaphane</kwd>
<kwd>TrkB</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source id="cn001">Japan Society for the Promotion of Science London<named-content content-type="fundref-id">10.13039/501100000646</named-content></funding-source>
<award-id rid="cn001">17H04243</award-id>
</award-group>
<award-group>
<funding-source id="cn002">Japan Agency for Medical Research and Development<named-content content-type="fundref-id">10.13039/100009619</named-content></funding-source>
<award-id rid="cn002">JP18dm0107119</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="5"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="105"></ref-count>
<page-count count="11"></page-count>
<word-count count="0"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec>
<title>Introduction</title>
<p>Depression, one of the most common psychiatric disorders in the world, is a mood disorder with a high rate of relapse. The World Health Organization (WHO) estimates that more than 320 million individuals of all ages suffer from depression, highlighting this disease as a major contributor to the global burden of disease (<xref ref-type="bibr" rid="B85">World Health Organization [WHO], 2017</xref>). Although the precise mechanisms underlying the pathophysiology of depression are currently unknown, accumulating evidence implicate inflammatory processes in the pathophysiology of depression (<xref ref-type="bibr" rid="B7">Dantzer et al., 2008</xref>; <xref ref-type="bibr" rid="B19">Hashimoto, 2009</xref>; <xref ref-type="bibr" rid="B54">Miller et al., 2009</xref>; <xref ref-type="bibr" rid="B67">Raison et al., 2010</xref>; <xref ref-type="bibr" rid="B22">Hashimoto, 2015</xref>; <xref ref-type="bibr" rid="B49">Mechawar and Savitz, 2016</xref>; <xref ref-type="bibr" rid="B55">Miller and Raison, 2016</xref>; <xref ref-type="bibr" rid="B104">Zhang et al., 2016</xref>; <xref ref-type="bibr" rid="B53">Miller et al., 2017</xref>). Meta-analysis demonstrated higher levels of pro-inflammatory cytokines in the blood of drug-free or medicated depressed patients compared to healthy controls (<xref ref-type="bibr" rid="B12">Dowlati et al., 2010</xref>; <xref ref-type="bibr" rid="B97">Young et al., 2014</xref>; <xref ref-type="bibr" rid="B18">Haapakoski et al., 2015</xref>; <xref ref-type="bibr" rid="B31">Köhler et al., 2018</xref>). Studies demonstrated elevated gene expression of pro-inflammatory cytokines in the postmortem brain samples from patients with a history of depression (<xref ref-type="bibr" rid="B9">Dean et al., 2010</xref>; <xref ref-type="bibr" rid="B72">Shelton et al., 2011</xref>). Collectively, it is likely that inflammation plays a key role in the pathophysiology of depression.</p>
<p>Over the past decade, there has been increasing interest in the potential benefits of early intervention for mood disorders. Several lines of evidence suggest that nutrition has a high impact on the development of depression (<xref ref-type="bibr" rid="B38">Lin et al., 2010</xref>; <xref ref-type="bibr" rid="B57">Murakami and Sasaki, 2010</xref>; <xref ref-type="bibr" rid="B4">Bazinet and Layé, 2014</xref>; <xref ref-type="bibr" rid="B50">Mello et al., 2014</xref>; <xref ref-type="bibr" rid="B14">El-Behadli et al., 2015</xref>; <xref ref-type="bibr" rid="B64">Opie et al., 2015</xref>; <xref ref-type="bibr" rid="B37">Lin et al., 2017</xref>; <xref ref-type="bibr" rid="B27">Hsu et al., 2018</xref>; <xref ref-type="bibr" rid="B81">Wang et al., 2018</xref>). Recent meta-analyses demonstrated that high intake of fruit, vegetables, fish, and whole grains are associated with a lower risk of depression (<xref ref-type="bibr" rid="B35">Lai et al., 2014</xref>; <xref ref-type="bibr" rid="B39">Liu et al., 2016</xref>; <xref ref-type="bibr" rid="B69">Saghafian et al., 2018</xref>).</p>
<p>In the review, the author would like to discuss the role of Keap1 [Kelch-like erythroid cell-derived protein with CNC homology [ECH]-associated protein 1)]-Nrf2 [Nuclear factor (erythroid 2-derived)-like 2] system in the pathophysiology of depression since Keap1-Nrf2 system plays a key role in inflammation. Furthermore, we also refer to the clinical significance of natural Nrf2 activator sulforaphane (SFN) as nutritional intervention for mood disorders.</p>
</sec>
<sec>
<title>Keap1-Nrf2 System</title>
<p>Nrf2 is the transcription factor with a key role in cellular defense against oxidative stress. It binds to the antioxidant response elements (ARE) located in the promoter region of genes encoding many phase II detoxifying or antioxidant enzymes and related stress-responsive proteins (<xref ref-type="bibr" rid="B30">Kobayashi et al., 2013</xref>; <xref ref-type="bibr" rid="B43">Ma, 2013</xref>; <xref ref-type="bibr" rid="B77">Suzuki et al., 2013a</xref>; <xref ref-type="bibr" rid="B79">Suzuki and Yamamoto, 2015</xref>; <xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). Under normal conditions, Nrf2 is repressed by Keap1, which is an adaptor protein for the degradation of Nrf2 (<xref ref-type="bibr" rid="B77">Suzuki et al., 2013a</xref>; <xref ref-type="bibr" rid="B79">Suzuki and Yamamoto, 2015</xref>). During oxidative stress, Nrf2 is de-repressed and activates the transcription of protective genes (<xref ref-type="bibr" rid="B77">Suzuki et al., 2013a</xref>; <xref ref-type="bibr" rid="B79">Suzuki and Yamamoto, 2015</xref>). Importantly, the Keap1-Nrf2 system plays a role in inflammation-associated pathogenesis (<xref ref-type="bibr" rid="B30">Kobayashi et al., 2013</xref>; <xref ref-type="bibr" rid="B77">Suzuki et al., 2013a</xref>; <xref ref-type="bibr" rid="B60">O’Connell and Hayes, 2015</xref>; <xref ref-type="bibr" rid="B79">Suzuki and Yamamoto, 2015</xref>; <xref ref-type="bibr" rid="B83">Wardyn et al., 2015</xref>; <xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). In cancer cells, Nrf2 activation is beneficial and deleterious for the cancer-bearing host, depending on the time (initiation, promotion, and metastasis) and place (cancer cells or microenvironment) (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>).</p>
</sec>
<sec>
<title>Nrf2 Activators</title>
<p>Based on the role of Nrf2 in the prevention of a wide variety of pathological conditions, great efforts have been made to isolate from natural sources or develop potent and specific Nrf2 activators (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). The potent anti-inflammatory and naturally occurring compound sulforaphane (SFN: 1-isothiocyanato-4-methylsulfinylbutane) is an organosulfur compound derived from a glucosinolate precursor glucoraphanin (a glucosinolate, or β-thioglucoside-<italic>N</italic>-hydroxysulfate) (<bold>Figure <xref ref-type="fig" rid="F1">1</xref></bold>) found in cruciferous vegetables, such as broccoli sprout (<xref ref-type="bibr" rid="B105">Zhang et al., 1992</xref>; <xref ref-type="bibr" rid="B16">Fahey et al., 1997</xref>; <xref ref-type="bibr" rid="B34">Kwak and Kensler, 2010</xref>; <xref ref-type="bibr" rid="B29">Kensler et al., 2013</xref>; <xref ref-type="bibr" rid="B15">Fahey et al., 2015</xref>). It is well known that glucoraphanin can be converted to SFN by the endogenous enzyme, myrosinase (<xref ref-type="bibr" rid="B15">Fahey et al., 2015</xref>). Beneficial effect by SFN is thought to be mediated via activation of the Nrf2 pathway with subsequent up-regulation of phase II detoxification enzymes and antioxidant proteins, through ARE (<xref ref-type="bibr" rid="B77">Suzuki et al., 2013a</xref>; <xref ref-type="bibr" rid="B79">Suzuki and Yamamoto, 2015</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Chemical structure of sulphoraphane (SFN) and its precursor glucoraphanin. Cruciferous vegetables contain glucoraphanin, a glucosinolate derivative of sulforaphane (SFN).</p>
</caption>
<graphic xlink:href="fphar-09-01182-g001"></graphic>
</fig>
<p>TBE-31 [(±)-(4bS,8aR,10aS)-10a-ethynyl-4b,8,8-trimethyl-3,7-dioxo-3,4b,7,8,8a,9,10,10a-octahydrophenanthrene-2,6-dicarbonitrile] and MCE-1 [(±)-3-ethynyl-3-methyl-6-oxocyclohexa-1,4-dienecarbonitrile] are the novel Nrf2 activators (<xref ref-type="bibr" rid="B25">Honda et al., 2007</xref>; <xref ref-type="bibr" rid="B10">Dinkova-Kostova et al., 2010</xref>; <xref ref-type="bibr" rid="B26">Honda et al., 2011</xref>; <xref ref-type="bibr" rid="B32">Kostov et al., 2015</xref>; <bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>). Dimethyl fumarate (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>) is a new oral drug for the treatment of multiple sclerosis, and has neuroprotective effects via Nrf2-dependent antioxidant response (<xref ref-type="bibr" rid="B3">Al-Jaderi and Maghazachi, 2016</xref>; <xref ref-type="bibr" rid="B56">Mills et al., 2018</xref>). Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me (<bold>Figure <xref ref-type="fig" rid="F2">2</xref></bold>), is one of the derivatives of synthetic triterpenoids. Bardoxolone methyl has been used for the treatment of cancer (including leukemia and solid tumors), chronic kidney disease, and other diseases (<xref ref-type="bibr" rid="B82">Wang et al., 2014</xref>). Clinical trial of bardoxolone methyl is undergoing for diabetic nephropathy in Japan (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>), although its development was paused in the United States due to the occurrence of cardiac complications in patients with end-stage renal disease (<xref ref-type="bibr" rid="B66">Pergola et al., 2011</xref>; <xref ref-type="bibr" rid="B8">de Zeeuw et al., 2013</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Chemical structure of Nrf2 activators (TBE-31, MCE-1, dimethyl fumarate, bardoxolone methyl).</p>
</caption>
<graphic xlink:href="fphar-09-01182-g002"></graphic>
</fig>
</sec>
<sec>
<title>Effects of Nrf2 Activators on Neurite Outgrowth</title>
<p>The neuronal plasticity, including neurite outgrowth and neuroprotection, plays crucial role in the beneficial effect of therapeutic drugs in cellular level (<xref ref-type="bibr" rid="B40">Lu and Dwyer, 2005</xref>; <xref ref-type="bibr" rid="B84">Williams and Dwyer, 2009</xref>). <xref ref-type="bibr" rid="B96">Yao et al. (2016b)</xref> reported that SFN increased the number of cell with neurite outgrowth in PC12 cells. Furthermore, the potentiating effects of SFN on NGF-induced neurite outgrowth were blocked by treatment with <italic>Nrf2</italic> siRNA, but not the negative control (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>), suggesting that SFN can potentiate NGF-induced neurite outgrowth via activation of Nrf2.</p>
<p><xref ref-type="bibr" rid="B95">Yao et al. (2016a)</xref> reported that TBE-31 and MCE-1 also potentiated NGF-induced neurite outgrowth in PC12 cells. The <italic>Nrf2</italic> siRNA blocked the potentiating effects of TBE-31 and MCE-1 on neurite outgrowth in PC12 cells. Astragaloside IV is also reported to attenuate lead-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway (<xref ref-type="bibr" rid="B98">Yu et al., 2017</xref>). Collectively, it is likely that Nrf2 activators can promote neurite outgrowth through Nrf2 activation (<xref ref-type="bibr" rid="B90">Yang et al., 2015c</xref>; <xref ref-type="bibr" rid="B95">Yao et al., 2016a</xref>,<xref ref-type="bibr" rid="B96">b</xref>).</p>
</sec>
<sec>
<title>Alterations in Keap1-Nrf2 Signaling in Rodents with Depression-Like Phenotype</title>
<p>Chronic social defeat stress (CSDS) model has been used widely as an animal model of depression (<xref ref-type="bibr" rid="B33">Krishnan and Nestler, 2008</xref>; <xref ref-type="bibr" rid="B59">Nestler and Hyman, 2010</xref>; <xref ref-type="bibr" rid="B17">Golden et al., 2011</xref>). Susceptible mice with depression-like phenotype after CSDS have higher blood levels of pro-inflammatory cytokines [e.g., tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, and IL-1β] (<xref ref-type="bibr" rid="B101">Zhang et al., 2017a</xref>).</p>
<p>Western blot analysis showed that protein levels of Keap1 and Nrf2 in the CA3, DG, and PFC from mice with depression-like phenotype were significantly lower than those of control mice (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). In contrast, protein levels of Keap1 and Nrf2 in the CA1 and NAc were not different compared to control (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). These findings suggest that lower levels of Keap1 and Nrf2 in the CA3, DG, and PFC may be involved in depression-like phenotypes after CSDS.</p>
<p>Learned helplessness (LH) model has been also used as an animal model of depression (<xref ref-type="bibr" rid="B33">Krishnan and Nestler, 2008</xref>). In the LH paradigm, approximately 20–40% rats are resilient to inescapable stress (<xref ref-type="bibr" rid="B91">Yang et al., 2015a</xref>,<xref ref-type="bibr" rid="B92">b</xref>; <xref ref-type="bibr" rid="B89">Yang et al., 2016</xref>). LH (susceptible) rats have higher blood levels of IL-6 than control and resilient rats (<xref ref-type="bibr" rid="B91">Yang et al., 2015a</xref>), suggesting that peripheral inflammation may contribute to resilience versus susceptibility to stress. Protein levels of Keap1 and Nrf2 in the PFC and DG of hippocampus from LH (susceptible) rats were lower than control and non-LH (resilient) rats (<xref ref-type="bibr" rid="B100">Zhang et al., 2018</xref>). These results suggest that Keap1-Nrf2 signaling may contribute to stress resilience which is involved in the pathophysiology of major psychiatric disorders (<xref ref-type="bibr" rid="B100">Zhang et al., 2018</xref>).</p>
</sec>
<sec>
<title>Alterations in Keap1-Nrf2 Signaling in Samples from Patients with Major Depressive Disorder</title>
<p>Major depressive disorder (MDD) patients (<italic>n</italic> = 30) exhibited higher levels of Nrf2 and its regulator Keap1, as well as NF-κB in the cytoplasm of peripheral blood mononuclear cells compared to healthy controls (<italic>n</italic> = 35), suggesting that depression may be characterized by up-regulation of the transcription factor Keap1-Nrf2 (<xref ref-type="bibr" rid="B41">Lukic et al., 2014</xref>). Using genome-wide transcriptional profiling and promoter-based bioinformatic strategies, <xref ref-type="bibr" rid="B51">Mellon et al. (2016)</xref> measured leukocyte transcription factor (TF) activity in leukocytes from un-medicated MDD subjects (<italic>n</italic> = 20) versus age- and sex-matched healthy controls (<italic>n</italic> = 20). In leukocytes from un-medicated MDD subjects, the bioinformatic analysis showed an increased transcriptional activity of cAMP response element-binding/activating TF (CREB/ATF) and increased activity of TFs associated with Nrf2. Antidepressant therapy for 8 weeks was associated with significant reductions in depressive symptoms and reduced activity of Nrf2, but not in CREB/ATF activity. By contrast, other transcriptional regulation pathways, including nuclear factor kappa-B cells (NF-κB), early growth response proteins 1-4 (EGR1-4), the glucocorticoid receptor, and interferon-responsive TFs, showed either no difference as a function of disease or treatment. These results suggest that Nrf2 signaling may contribute to MDD by activating immune cell transcriptome dynamics that ultimately may influence motivational and affective processes via circulating mediators (<xref ref-type="bibr" rid="B51">Mellon et al., 2016</xref>).</p>
<p>Postmortem tissue from patients with psychiatric disorders is an underutilized substance that may be used to translate genetic and/or preclinical studies (<xref ref-type="bibr" rid="B23">Hashimoto et al., 2007</xref>; <xref ref-type="bibr" rid="B48">McCullumsmith et al., 2013</xref>; <xref ref-type="bibr" rid="B49">Mechawar and Savitz, 2016</xref>; <xref ref-type="bibr" rid="B88">Yang et al., 2017</xref>). A study using postmortem brain samples showed decreased expressions of Keap1 and Nrf2 in the parietal cortex from patients with MDD and bipolar disorder compared to control group (<xref ref-type="bibr" rid="B100">Zhang et al., 2018</xref>). A recent study showed the reduced (-21%) expression of Nrf2 in the dorsolateral prefrontal cortex from MDD patients (<xref ref-type="bibr" rid="B45">Martín-Hernández et al., 2018</xref>). These results suggest that decreased Keap1-Nrf2 signaling plays a key role in the pathophysiology of mood disorders such as MDD and bipolar disorder (<xref ref-type="bibr" rid="B100">Zhang et al., 2018</xref>).</p>
</sec>
<sec>
<title>Single Nucleotide Polymorphisms in the <italic>Nrf2</italic> Promoter Gene in Humans</title>
<p>The NRF2 activity in humans is regulated through protein stabilization, primarily by KEAP1, but is also regulated at the transcriptional level (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). In humans, a <italic>NRF2</italic> promotor single nucleotide polymorphism (SNP: rs6721961) located 617 bp by upstream from the transcription start site lowers the level of <italic>NRF2</italic> transcription (<xref ref-type="bibr" rid="B87">Yamamoto et al., 2006</xref>; <xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>; <bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Luciferase assays showed that polymorphism at position -617 (C to A) affect basal levels of NRF2, thereby resulting in attenuation of ARE-mediated gene transcription (<xref ref-type="bibr" rid="B46">Marzec et al., 2007</xref>; <bold>Figure <xref ref-type="fig" rid="F3">3</xref></bold>). Interestingly, subjects who possess this SNP are more susceptible to acute lung injury and related diseases (<xref ref-type="bibr" rid="B46">Marzec et al., 2007</xref>), and this SNP is also found to correlate with the incidence of non-small cell lung cancer (<xref ref-type="bibr" rid="B78">Suzuki et al., 2013b</xref>). In addition, ethnic difference of this SNP is also reported (<xref ref-type="bibr" rid="B46">Marzec et al., 2007</xref>). Therefore, it is of interest to study whether this SNP can affect susceptibility to mood disorders.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>SNP (rs6721961) in the promotor region of <italic>NRF2</italic> gene. The SNP (rs6721961) in the promotor of <italic>NRF2</italic> gene alters the transcription level of <italic>NRF2</italic> gene, resulting in alterations in the expression of <italic>NRF2</italic> target genes. The NRF2/sMAF (small MAF) protein complex regulates the oxidative stress response by occupying <italic>cis</italic>-acting enhancers containing an antioxidant response element (ARE). A slight modification of <xref ref-type="bibr" rid="B86">Yamamoto et al. (2018)</xref>.</p>
</caption>
<graphic xlink:href="fphar-09-01182-g003"></graphic>
</fig>
</sec>
<sec>
<title>Depression-Like Phenotypes in <italic>Nrf2</italic> KO Mice</title>
<p>Serum levels of TNF-α, IL-6, IL-10, and IL-1β in the <italic>Nrf2</italic> KO mice were significantly higher than those of wild-type (WT) mice, suggesting that <italic>Nrf2</italic> KO mice have inflammation (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). In the tail-suspension test (TST) and forced swimming test (FST), the immobility times of TST and FST in <italic>Nrf2</italic> KO mice were higher than those of WT mice. In the 1% sucrose preference test (SPT), the sucrose preference of <italic>Nrf2</italic> KO mice was lower than that of WT mice, suggesting that <italic>Nrf2</italic> KO mice have anhedonia. Furthermore, brain-derived neurotrophic factor (BDNF) and its receptor TrkB signaling in the CA3, DG and PFC of <italic>Nrf2</italic> KO mice were lower than those of WT mice. Moreover, protein levels of AMPA receptor 1 (GluA1) and postsynaptic density protein 95 (PSD-95) in the CA3, DG, and PFC of KO mice were lower than those of WT mice. Interestingly, 7,8-dihydroxyflavone (a TrkB agonist) produced antidepressant effects in <italic>Nrf2</italic> KO mice, by stimulating TrkB in the PFC, CA3, and DG (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). Furthermore, the anti-inflammatory drug rofecoxib reversed depression-like behaviors in <italic>Nrf2</italic> KO mice (<xref ref-type="bibr" rid="B44">Martín-de-Saavedra et al., 2013</xref>). In addition, chronic treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine increased BDNF in cortex and hippocampus of corticosterone-treated <italic>Nrf2</italic> KO mice (<xref ref-type="bibr" rid="B52">Mendez-David et al., 2015</xref>), suggesting that Nrf2 signaling contributes to fluoxetine-induced neuroprotection. These all findings suggest that Nrf2 plays a key role in the depression-like phenotypes in rodents through potent anti-inflammatory action. Collectively, it is likely that <italic>Nrf2</italic> KO mice show depression-like phenotypes through inflammation, decreased BDNF-TrkB signaling and synaptogenesis (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>; <xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>).</p>
<p>In contrast, <xref ref-type="bibr" rid="B5">Bouvier et al. (2017)</xref> reported that <italic>Nrf2</italic> KO mice did not display a depression-like phenotype although the KO mice were characterized by oxidative stress and by anatomical alterations in hippocampal CA3 pyramidal cells. However, when exposed to 3 weeks of chronic mild stress, <italic>Nrf2</italic> KO mice developed depression-like phenotypes which were prevented by pretreatment with antioxidant (<xref ref-type="bibr" rid="B5">Bouvier et al., 2017</xref>). This study also suggests the role of Nrf2-dependent persistent oxidative stress in stress-induced vulnerability to depression.</p>
</sec>
<sec>
<title>Antidepressant Effects of Nrf2 Activators in the Rodent Models of Depression</title>
<p>When lipopolysaccharide (LPS), the bacterial endotoxin, is administered to rodents, depression-like behaviors are observed 24 h after inflammation (<xref ref-type="bibr" rid="B7">Dantzer et al., 2008</xref>; <xref ref-type="bibr" rid="B61">O’Connor et al., 2009</xref>; <xref ref-type="bibr" rid="B99">Zhang et al., 2014</xref>; <xref ref-type="bibr" rid="B104">Zhang et al., 2016</xref>). Pretreatment with antidepressants, such as SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs), can prevent depression-like behavior and alterations in serum pro-inflammatory cytokines, such as TNF-α, induced by LPS administration (<xref ref-type="bibr" rid="B63">Ohgi et al., 2013</xref>; <xref ref-type="bibr" rid="B94">Yao et al., 2015</xref>; <xref ref-type="bibr" rid="B11">Dong et al., 2016</xref>). These all findings suggest that inflammation is associated with depression, and that anti-inflammatory drugs could ameliorate depressive symptoms in patients with depression.</p>
<p>Pretreatment with SFN significantly blocked an increase in the serum TNF-α level after a single administration of LPS (<xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>). Furthermore, SFN significantly potentiated increased serum levels of IL-10 after LPS administration. SFN attenuated an increase of the immobility time of TST and FST after LPS administration. In addition, SFN recovered to control levels for LPS-induced alterations in the proteins such as BDNF, PSD-95 and GluA1, and dendritic spine density in the brain regions (<xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>). Furthermore, TBE-31 or MCE-1 attenuated an increase in serum levels of TNF-α after LPS administration. Administration of TBE-31 or MCE-1 attenuated an increase in the immobility time of TST and FST after LPS administration (<xref ref-type="bibr" rid="B95">Yao et al., 2016a</xref>).</p>
<p>Pretreatment with SFN attenuated the decreased social avoidance time and sucrose preference in CSDS model. Furthermore, SFN could attenuate the decreased levels of Nrf2 and Keap1 proteins in the PFC and hippocampus of mice with depression-like phenotype (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). <xref ref-type="bibr" rid="B36">Li et al. (2018)</xref> reported that decreased Keap1-Nrf2 signaling in the PFC, hippocampus and skeletal muscle may contribute to anhedonia susceptibility after spared nerve injury (SNI), and that SFN exerts beneficial effects in SNI rats by normalization of decreased Keap1-Nrf2 signaling. These results suggest that Keap1-Nrf2 signaling plays a role in depression, and that SFN is prophylactic compound which can stimulate Keap1-Nrf2 signaling pathway (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>; <xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>; <xref ref-type="bibr" rid="B36">Li et al., 2018</xref>). Taken all together, it is likely that the Nrf2 activators such as SFN, TBE-31, and MCE-1 might be potential prophylactic or therapeutic drugs for inflammation (or stress)-related depression (<xref ref-type="bibr" rid="B95">Yao et al., 2016a</xref>,<xref ref-type="bibr" rid="B96">b</xref>; <xref ref-type="bibr" rid="B104">Zhang et al., 2016</xref>, <xref ref-type="bibr" rid="B103">2017b</xref>; <xref ref-type="bibr" rid="B36">Li et al., 2018</xref>).</p>
</sec>
<sec>
<title>Effects of Dietary Intake of SFN Precursor in the CSDS Model of Depression</title>
<p>SFN is produced in the body from its precursor glucoraphanin which is involved in cruciferous vegetables. Previously, we demonstrated that dietary intake of 0.1% glucoraphanin –rich food during juvenile and adolescence prevented phencyclidine-induced cognitive deficits and loss of parvalbumin (PV)-positive cells in the PFC at adulthood (<xref ref-type="bibr" rid="B74">Shirai et al., 2015</xref>). Furthermore, we also reported that dietary intake of 0.1% glucoraphanin –rich food during juvenile and adolescence prevented the onset of psychosis in the adult offspring after maternal immune activation (<xref ref-type="bibr" rid="B47">Matsuura et al., 2018</xref>). These findings suggest that dietary-intake of glucoraphanin-rich vegetables in high-risk psychosis subjects might prevent the transition to psychosis in young adulthood (<xref ref-type="bibr" rid="B21">Hashimoto, 2014</xref>; <xref ref-type="bibr" rid="B74">Shirai et al., 2015</xref>; <xref ref-type="bibr" rid="B47">Matsuura et al., 2018</xref>).</p>
<p>Interestingly, dietary intake of 0.1% glucoraphanin containing food during juvenile and adolescent stages could prevent the depression-like phenotype in adulthood after CSDS (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>). Thus, the dietary intake of 0.1% glucoraphanin containing food during juvenile and adolescent periods could confer stress resilience in adulthood.</p>
</sec>
<sec>
<title>Clinical Study of SFN in Patients with Healthy Subjects, and Neurodevelopmental Disorders</title>
<p><xref ref-type="bibr" rid="B71">Sedlak et al. (2018)</xref> reported that SFN increased blood glutathione (GSH) levels in healthy human subjects following 7 days of daily oral administration. Furthermore, a significant positive correlation between blood and thalamic GSH post- and pre-SFN treatment ratios was observed, in addition to a consistent increase in brain GSH levels in response to treatment. This study suggests the value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences SFN has on functional measures that are altered in neuropsychiatric disorders.</p>
<p>A randomized, double-blinded, placebo-controlled study showed that SFN-rich broccoli sprout extract could improve social interaction, abnormal behavior and verbal communication in young male subjects with autism spectrum disorder (<xref ref-type="bibr" rid="B76">Singh et al., 2014</xref>; <xref ref-type="bibr" rid="B42">Lynch et al., 2017</xref>). In addition, a pilot study showed that supplementation with glucoraphanin-rich broccoli sprout extract for 8 weeks was effective in treating cognitive impairment in medicated patients with schizophrenia (<xref ref-type="bibr" rid="B73">Shiina et al., 2015</xref>). Collectively, it is likely that SFN would be potential therapeutic compound for neurodevelopmental disorders.</p>
</sec>
<sec>
<title>Role of Nrf2 in the Mechanisms of Antidepressant Action for Other Potential Compounds</title>
<p>Cilostazol is used in the treatment of the symptoms of intermittent claudication in patients with peripheral vascular disease. In the chronic restraint stress (CRS) model, cilostazol prevented depressive-like behaviors (<xref ref-type="bibr" rid="B2">Abuelezz and Hendawy, 2018</xref>). Furthermore, cilostazol modulated the Nrf2 protein and heme oxygenase-1 and NAD(P)H: quinone oxidoreductase-1 gene expression in the hippocampus of CRS rats. These findings suggest that cilostazol has the prophylactic antidepressant effect by preventing oxidative stress by stimulation of redox defense mechanisms mediated through the Nrf2 pathway (<xref ref-type="bibr" rid="B2">Abuelezz and Hendawy, 2018</xref>).</p>
<p>Dl-3-n-Butylphthalide (NBP), a small molecule compound extracted from the seeds of <italic>Apium graveolens</italic>, was approved by the State Food and Drug Administration of China for treating ischemic stroke (<xref ref-type="bibr" rid="B1">Abdoulaye and Yi, 2016</xref>). NBP attenuated the depression-like behaviors and increased expression of pro-inflammatory cytokines (e.g., IL-1β and IL-6) in rats. In addition with the anti-inflammation action, NBP reduced LPS-induced oxidative stress reactions in the hippocampus and enhanced Nrf2-targeted signals (<xref ref-type="bibr" rid="B93">Yang et al., 2018</xref>).</p>
<p>A randomized, double-blind, placebo-controlled trial showed that NBP showed greater effects than placebo on Alzheimer’s disease assessment scale-cognitive subscale (ADAS-cog) and clinician’s interview-based impression of change plus caregiver input (CIBIC-plus). NBP-related adverse events were uncommon and primarily consisted of mild gastrointestinal symptoms (<xref ref-type="bibr" rid="B28">Jia et al., 2016</xref>). Therefore, it is of interest to examine whether NBP can improve depressive symptoms in depressed patients.</p>
</sec>
<sec>
<title>Nrf2 Inhibitors</title>
<p>Compared with Nrf2 activators, the development of Nrf2 inhibitors is in its infancy (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). For example, cancers with persistent activation of Nrf2 exhibit high dependency on Nrf2 function for drug resistance and cell proliferation (<xref ref-type="bibr" rid="B86">Yamamoto et al., 2018</xref>). The plant-based product brusatol (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>) decreases the protein levels of Nrf2 and sensitizes cancer cells to chemotherapy and radiotherapy (<xref ref-type="bibr" rid="B68">Ren et al., 2011</xref>). Another Nrf2 inhibitor halofuginone (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>) is a synthetic halogenated derivative of febrifugine, a natural quinazolinone alkaloid which can be found in the Chinese herb <italic>Dichroa febrifuga</italic>. Halofuginone exerts a chemosensitizing effect on cancer cells exhibiting constitutive Nrf2 stabilization (<xref ref-type="bibr" rid="B80">Tsuchida et al., 2017</xref>). In addition, <xref ref-type="bibr" rid="B75">Singh et al. (2016)</xref> demonstrated that ML385 [<italic>N</italic>-[4-[2,3-dihydro-1-(2-methylbenzoyl)-1H-indol-5-yl]-5-methyl-2-thiazolyl]-1,3-benzodioxole-5-acetamide] (<bold>Figure <xref ref-type="fig" rid="F4">4</xref></bold>) is a novel and specific Nrf2 inhibitor. Therefore, it is of interest to study whether these Nrf2 inhibitors can affect depression-like phenotypes in rodents.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>Chemical structure of Nrf2 inhibitors (brustal, halofuginone, ML-385).</p>
</caption>
<graphic xlink:href="fphar-09-01182-g004"></graphic>
</fig>
</sec>
<sec>
<title>Conclusion Remarks and Future Perspective</title>
<p>Rodents with depression-like phenotype have higher blood levels of pro-inflammatory cytokines, suggesting that inflammation plays a role in depression-like phenotype in rodents. Furthermore, rodents with depression-like phenotype have lower expression of Keap1 and Nrf2 in the PFC and hippocampus (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>; <xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>). Interestingly, we found decreased expression of Keap1 and Nrf2 in the parietal cortex from patients with MDD and bipolar disorder (<xref ref-type="bibr" rid="B100">Zhang et al., 2018</xref>). Given the essential role of BDNF-TrkB signaling in depression (<xref ref-type="bibr" rid="B58">Nestler et al., 2002</xref>; <xref ref-type="bibr" rid="B24">Hashimoto et al., 2004</xref>; <xref ref-type="bibr" rid="B13">Duman and Monteggia, 2006</xref>; <xref ref-type="bibr" rid="B20">Hashimoto, 2010</xref>; <xref ref-type="bibr" rid="B104">Zhang et al., 2016</xref>), inflammation (or stress)-induced reduction of Keap1-Nrf2 system may contribute to decreased BDNF-TrkB signaling and synaptogenesis, resulting in depression-like phenotypes (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>). It is noteworthy that TrkB agonist 7,8-DHF has antidepressant effects in <italic>Nrf2</italic> KO mice (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>), LPS-treated mice (<xref ref-type="bibr" rid="B99">Zhang et al., 2014</xref>) and CSDS susceptible mice (<xref ref-type="bibr" rid="B102">Zhang et al., 2015</xref>), suggesting a possible link between Keap1-Nrf2 system and BDNF-TrkB signaling (<xref ref-type="bibr" rid="B52">Mendez-David et al., 2015</xref>; <xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>; <xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>; <xref ref-type="bibr" rid="B36">Li et al., 2018</xref>; <bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>).</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>Proposed hypothesis of role of Keap1-Nrf2 system in depression. Inflammation causes decreases of Keap1 and Nrf2 expression in the prefrontal cortex and hippocampus. Subsequently, inflammation-induced decreases in Keap1 and Nrf2 proteins can cause the decreased BDNF-TrkB signaling and synaptogenesis, resulting in depression-like phenotype. TrkB agonists might have antidepressant actions. Dietary intake of glucoraphanin (or SFN) in cruciferous vegetables during early adolescence may confer to stress resilience at adulthood whereas poor nutrition may play a role in the onset of depression by stress or inflammation.</p>
</caption>
<graphic xlink:href="fphar-09-01182-g005"></graphic>
</fig>
<p>Nutritional status during early adolescence stage might have a great impact on the onset and severity of psychiatric diseases in adulthood (<xref ref-type="bibr" rid="B65">Paus et al., 2008</xref>; <xref ref-type="bibr" rid="B62">O’Connor and Cryan, 2014</xref>). Over the past decade, there has been increasing interest in the potential benefits of early intervention for psychiatric disorders such as depression (<xref ref-type="bibr" rid="B65">Paus et al., 2008</xref>; <xref ref-type="bibr" rid="B62">O’Connor and Cryan, 2014</xref>; <xref ref-type="bibr" rid="B70">Sarris et al., 2015</xref>; <xref ref-type="bibr" rid="B6">Correll et al., 2018</xref>).</p>
<p>Preclinical findings suggest that dietary intake of glucoraphanin during juvenile and adolescence can protect against depression-like behaviors after CSDS or LPS administration (<xref ref-type="bibr" rid="B96">Yao et al., 2016b</xref>; <xref ref-type="bibr" rid="B103">Zhang et al., 2017b</xref>), indicating prophylactic effects of glucoraphanin for depression. Thus, dietary intake of glucoraphanin (or SFN) during juvenile and adolescence might confer stress resilience at adulthood (<bold>Figure <xref ref-type="fig" rid="F5">5</xref></bold>). Therefore, it is possible that dietary intake of glucoraphanin (or SFN) during childhood and adolescence stages could prevent the onset of depression in humans during adulthood. Since patients with mood disorder have high relapse rate, dietary intake of glucoraphanin (or SFN) may prevent or minimize relapse from remission, induced by inflammation and/or stress in depressed patients.</p>
</sec>
<sec>
<title>Author Contributions</title>
<p>The author confirms being the sole contributor of this work and approved it for publication.</p>
</sec>
<sec>
<title>Conflict of Interest Statement</title>
<p>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported by grants from JSPS KAKENHI (to KH, 17H04243), and AMED, Japan (to KH, JP18dm0107119).</p>
</fn>
</fn-group>
<ack>
<p>I would like to thank my collaborators who are listed as the co-authors of our papers in the reference list.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdoulaye</surname><given-names>I. A.</given-names></name><name><surname>Yi</surname><given-names>J. G.</given-names></name></person-group> (<year>2016</year>). <article-title>A review of recent advances in neuroprotective potential of 3-N-butylphthalide and its derivatives.</article-title>
<source/><italic>Biomed. Res. Int.</italic>
<volume>2016</volume>:<issue>5012341</issue>. <pub-id pub-id-type="doi">10.1155/2016/5012341</pub-id>
<pub-id pub-id-type="pmid">28053983</pub-id></mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuelezz</surname><given-names>S. A.</given-names></name><name><surname>Hendawy</surname><given-names>N.</given-names></name></person-group> (<year>2018</year>). <article-title>Insights into the potential antidepressant mechanisms of cilostazol in chronically restraint rats: impact on the Nrf2 pathway.</article-title>
<source/><italic>Behav. Pharmacol.</italic>
<volume>29</volume>
<fpage>28</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1097/FBP.0000000000000335</pub-id>
<pub-id pub-id-type="pmid">28763303</pub-id></mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Jaderi</surname><given-names>Z.</given-names></name><name><surname>Maghazachi</surname><given-names>A. A.</given-names></name></person-group> (<year>2016</year>). <article-title>Utilization of dimethyl fumarate and related molecules for treatment of multiple sclerosis, cancer, and other diseases.</article-title>
<source/><italic>Front. Immunol.</italic>
<volume>7</volume>:<issue>278</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00278</pub-id>
<pub-id pub-id-type="pmid">27499754</pub-id></mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bazinet</surname><given-names>R. P.</given-names></name><name><surname>Layé</surname><given-names>S.</given-names></name></person-group> (<year>2014</year>). <article-title>Polyunsaturated fatty acids and their metabolites in brain function and disease.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>15</volume>
<fpage>771</fpage>–<lpage>785</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3820</pub-id>
<pub-id pub-id-type="pmid">25387473</pub-id></mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouvier</surname><given-names>E.</given-names></name><name><surname>Brouillard</surname><given-names>F.</given-names></name><name><surname>Molet</surname><given-names>J.</given-names></name><name><surname>Claverie</surname><given-names>D.</given-names></name><name><surname>Cabungcal</surname><given-names>J. H.</given-names></name><name><surname>Cresto</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Nrf2-dependent persistent oxidative stress results in stress-induced vulnerability to depression.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>22</volume>
<fpage>1701</fpage>–<lpage>1713</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.144</pub-id>
<pub-id pub-id-type="pmid">27646262</pub-id></mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Correll</surname><given-names>C. U.</given-names></name><name><surname>Galling</surname><given-names>B.</given-names></name><name><surname>Pawar</surname><given-names>A.</given-names></name><name><surname>Krivko</surname><given-names>A.</given-names></name><name><surname>Bonetto</surname><given-names>C.</given-names></name><name><surname>Ruggeri</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Comparison of early intervention services vs treatment as usual for early-phase psychosis: a systematic review, meta-analysis, and meta-regression.</article-title>
<source/><italic>JAMA Psychiatry</italic>
<volume>75</volume>
<fpage>555</fpage>–<lpage>565</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2018.0623</pub-id>
<pub-id pub-id-type="pmid">29800949</pub-id></mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dantzer</surname><given-names>R.</given-names></name><name><surname>O’Connor</surname><given-names>J. C.</given-names></name><name><surname>Freund</surname><given-names>G. G.</given-names></name><name><surname>Johnson</surname><given-names>R. W.</given-names></name><name><surname>Kelley</surname><given-names>K. W.</given-names></name></person-group> (<year>2008</year>). <article-title>From inflammation to sickness and depression: when the immune system subjugates the brain.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>9</volume>
<fpage>46</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2297</pub-id>
<pub-id pub-id-type="pmid">18073775</pub-id></mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Zeeuw</surname><given-names>D.</given-names></name><name><surname>Akizawa</surname><given-names>T.</given-names></name><name><surname>Audhya</surname><given-names>P.</given-names></name><name><surname>Bakris</surname><given-names>G. L.</given-names></name><name><surname>Chin</surname><given-names>M.</given-names></name><name><surname>Christ-Schmidt</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.</article-title>
<source/><italic>N. Eng. J. Med.</italic>
<volume>369</volume>
<fpage>2492</fpage>–<lpage>2503</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1306033</pub-id>
<pub-id pub-id-type="pmid">24206459</pub-id></mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dean</surname><given-names>B.</given-names></name><name><surname>Tawadros</surname><given-names>N.</given-names></name><name><surname>Scarr</surname><given-names>E.</given-names></name><name><surname>Gibbons</surname><given-names>A. S.</given-names></name></person-group> (<year>2010</year>). <article-title>Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder.</article-title>
<source/><italic>J. Affect. Disord.</italic>
<volume>120</volume>
<fpage>245</fpage>–<lpage>248</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2009.04.027</pub-id>
<pub-id pub-id-type="pmid">19446343</pub-id></mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dinkova-Kostova</surname><given-names>A. T.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><name><surname>Sharkey</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Holtzclaw</surname><given-names>W. D.</given-names></name><name><surname>Wang</surname><given-names>X. J.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1.</article-title>
<source/><italic>J. Biol. Chem.</italic>
<volume>285</volume>
<fpage>33747</fpage>–<lpage>33755</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M110.163485</pub-id>
<pub-id pub-id-type="pmid">20801881</pub-id></mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>144</volume>
<fpage>7</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2016.02.005</pub-id>
<pub-id pub-id-type="pmid">26892759</pub-id></mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowlati</surname><given-names>Y.</given-names></name><name><surname>Herrmann</surname><given-names>N.</given-names></name><name><surname>Swardfager</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Sham</surname><given-names>L.</given-names></name><name><surname>Reim</surname><given-names>E. K.</given-names></name><etal></etal></person-group> (<year>2010</year>). <article-title>A meta-analysis of cytokines in major depression.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>67</volume>
<fpage>446</fpage>–<lpage>457</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.09.033</pub-id>
<pub-id pub-id-type="pmid">20015486</pub-id></mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duman</surname><given-names>R. S.</given-names></name><name><surname>Monteggia</surname><given-names>L. M.</given-names></name></person-group> (<year>2006</year>). <article-title>A neurotrophic model for stress-related mood disorders.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>59</volume>
<fpage>1116</fpage>–<lpage>1127</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2006.02.013</pub-id>
<pub-id pub-id-type="pmid">16631126</pub-id></mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Behadli</surname><given-names>A. F.</given-names></name><name><surname>Sharp</surname><given-names>C.</given-names></name><name><surname>Hughes</surname><given-names>S. O.</given-names></name><name><surname>Obasi</surname><given-names>E. M.</given-names></name><name><surname>Nicklas</surname><given-names>T. A.</given-names></name></person-group> (<year>2015</year>). <article-title>Maternal depression, stress and feeding styles: towards a framework for theory and research in child obesity.</article-title>
<source/><italic>Br. J. Nutr.</italic>
<volume>113</volume>
<fpage>S55</fpage>–<lpage>S71</lpage>. <pub-id pub-id-type="doi">10.1017/S000711451400333X</pub-id>
<pub-id pub-id-type="pmid">25588385</pub-id></mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname><given-names>J. W.</given-names></name><name><surname>Holtzclaw</surname><given-names>W. D.</given-names></name><name><surname>Wehage</surname><given-names>S. L.</given-names></name><name><surname>Wade</surname><given-names>K. L.</given-names></name><name><surname>Stephenson</surname><given-names>K. K.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Sulforaphane bioavailability from glucoraphanin-rich broccoli: control by active endogenous myrosinase.</article-title>
<source/><italic>PLoS One</italic>
<volume>10</volume>:<issue>e0140963</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0140963</pub-id>
<pub-id pub-id-type="pmid">26524341</pub-id></mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahey</surname><given-names>J. W.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name></person-group> (<year>1997</year>). <article-title>Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>94</volume>
<fpage>10367</fpage>–<lpage>10372</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.94.19.10367</pub-id>
<pub-id pub-id-type="pmid">9294217</pub-id></mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>S. A.</given-names></name><name><surname>Covington</surname><given-names>H. E.</given-names></name><name><surname>Berton</surname><given-names>O.</given-names></name><name><surname>Russo</surname><given-names>S. J.</given-names></name></person-group> (<year>2011</year>). <article-title>A standardized protocol for repeated social defeat stress in mice.</article-title>
<source/><italic>Nat. Protoc.</italic>
<volume>6</volume>
<fpage>1183</fpage>–<lpage>1191</lpage>. <pub-id pub-id-type="doi">10.1038/nprot.2011.361</pub-id>
<pub-id pub-id-type="pmid">21799487</pub-id></mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haapakoski</surname><given-names>R.</given-names></name><name><surname>Mathieu</surname><given-names>J.</given-names></name><name><surname>Ebmeier</surname><given-names>K. P.</given-names></name><name><surname>Alenius</surname><given-names>H.</given-names></name><name><surname>Kivimäki</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder.</article-title>
<source/><italic>Brain Behav. Immun.</italic>
<volume>49</volume>
<fpage>206</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2015.06.001</pub-id>
<pub-id pub-id-type="pmid">26065825</pub-id></mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2009</year>). <article-title>Emerging role of glutamate in the pathophysiology of major depressive disorder.</article-title>
<source/><italic>Brain Res. Rev.</italic>
<volume>61</volume>
<fpage>1056</fpage>–<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2009.05.005</pub-id>
<pub-id pub-id-type="pmid">19481572</pub-id></mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions.</article-title>
<source/><italic>Psychiatry Clin. Neurosci.</italic>
<volume>64</volume>
<fpage>341</fpage>–<lpage>357</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1819.2010.02113.x</pub-id>
<pub-id pub-id-type="pmid">20653908</pub-id></mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Targeting of NMDA receptors in new treatments for schizophrenia.</article-title>
<source/><italic>Expert Opin. Ther. Targets</italic>
<volume>18</volume>
<fpage>1049</fpage>–<lpage>1063</lpage>. <pub-id pub-id-type="doi">10.1517/14728222.2014.934225</pub-id>
<pub-id pub-id-type="pmid">24965576</pub-id></mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2015</year>). <article-title>Inflammatory biomarkers as differential predictors of antidepressant response.</article-title>
<source/><italic>Int. J. Mol. Sci.</italic>
<volume>16</volume>
<fpage>7796</fpage>–<lpage>7801</lpage>. <pub-id pub-id-type="doi">10.3390/ijms16047796</pub-id>
<pub-id pub-id-type="pmid">25856677</pub-id></mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name><name><surname>Sawa</surname><given-names>A.</given-names></name><name><surname>Iyo</surname><given-names>M.</given-names></name></person-group> (<year>2007</year>). <article-title>Increased levels of glutamate in brains from patients with mood disorders.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>62</volume>
<fpage>1310</fpage>–<lpage>1316</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2007.03.017</pub-id>
<pub-id pub-id-type="pmid">17574216</pub-id></mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>K.</given-names></name><name><surname>Shimizu</surname><given-names>E.</given-names></name><name><surname>Iyo</surname><given-names>M.</given-names></name></person-group> (<year>2004</year>). <article-title>Critical role of brain-derived neurotrophic factor in mood disorders.</article-title>
<source/><italic>Brain Res. Rev.</italic>
<volume>45</volume>
<fpage>104</fpage>–<lpage>114</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresrev.2004.02.003</pub-id>
<pub-id pub-id-type="pmid">15145621</pub-id></mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Sundararajan</surname><given-names>C.</given-names></name><name><surname>Yoshizawa</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>X.</given-names></name><name><surname>Honda</surname><given-names>Y.</given-names></name><name><surname>Liby</surname><given-names>K. T.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Novel tricyclic compounds having acetylene groups at C-8a and cyano enones in rings A and C: highly potent anti-inflammatory and cytoprotective agents.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>50</volume>
<fpage>1731</fpage>–<lpage>1734</lpage>. <pub-id pub-id-type="doi">10.1021/jm070141c</pub-id>
<pub-id pub-id-type="pmid">17367124</pub-id></mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>T.</given-names></name><name><surname>Yoshizawa</surname><given-names>H.</given-names></name><name><surname>Sundararajan</surname><given-names>C.</given-names></name><name><surname>David</surname><given-names>E.</given-names></name><name><surname>Lajoie</surname><given-names>M. J.</given-names></name><name><surname>Favaloro</surname><given-names>F. G.</given-names><suffix>Jr.</suffix></name><etal></etal></person-group> (<year>2011</year>). <article-title>Tricyclic compounds containing nonenolizable cyano enones: a novel class of highly potent anti-inflammatory and cytoprotective agents.</article-title>
<source/><italic>J. Med. Chem.</italic>
<volume>54</volume>
<fpage>1762</fpage>–<lpage>1778</lpage>. <pub-id pub-id-type="doi">10.1021/jm101445p</pub-id>
<pub-id pub-id-type="pmid">21361338</pub-id></mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>M. C.</given-names></name><name><surname>Tung</surname><given-names>C. Y.</given-names></name><name><surname>Chen</surname><given-names>H. E.</given-names></name></person-group> (<year>2018</year>). <article-title>Omega-3 polyunsaturated fatty acid supplementation in prevention and treatment of maternal depression: putative mechanism and recommendation.</article-title>
<source/><italic>J. Affect. Disord.</italic>
<volume>238</volume>
<fpage>47</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2018.05.018</pub-id>
<pub-id pub-id-type="pmid">29860183</pub-id></mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Wei</surname><given-names>C.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>A.</given-names></name><name><surname>Zuo</surname><given-names>X.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>The effects of DL-3-n-butylphthalide in patients with vascular cognitive impairment without dementia caused by subcortical ischemic small vessel disease: a multicentre, randomized, double-blind, placebo-controlled trial.</article-title>
<source/><italic>Alzheimers Dement.</italic>
<volume>12</volume>
<fpage>89</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.jalz.2015.04.010</pub-id>
<pub-id pub-id-type="pmid">26086183</pub-id></mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kensler</surname><given-names>T. W.</given-names></name><name><surname>Egner</surname><given-names>P. A.</given-names></name><name><surname>Agyeman</surname><given-names>A. S.</given-names></name><name><surname>Visvanathan</surname><given-names>K.</given-names></name><name><surname>Groopman</surname><given-names>J. D.</given-names></name><name><surname>Chen</surname><given-names>J. G.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane.</article-title>
<source/><italic>Top Curr. Chem.</italic>
<volume>329</volume>
<fpage>163</fpage>–<lpage>177</lpage>. <pub-id pub-id-type="doi">10.1007/128_2012_339</pub-id>
<pub-id pub-id-type="pmid">22752583</pub-id></mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>E.</given-names></name><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group> (<year>2013</year>). <article-title>Roles Nrf2 plays in myeloid cells and related disorders.</article-title>
<source/><italic>Oxid. Med. Cell. Longev.</italic>
<volume>2013</volume>:<issue>529219</issue>. <pub-id pub-id-type="doi">10.1155/2013/529219</pub-id>
<pub-id pub-id-type="pmid">23819012</pub-id></mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Köhler</surname><given-names>C. A.</given-names></name><name><surname>Freitas</surname><given-names>T. H.</given-names></name><name><surname>Stubbs</surname><given-names>B.</given-names></name><name><surname>Maes</surname><given-names>M.</given-names></name><name><surname>Solmi</surname><given-names>M.</given-names></name><name><surname>Veronese</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis.</article-title>
<source/><italic>Mol. Neurobiol.</italic>
<volume>55</volume>
<fpage>4195</fpage>–<lpage>4206</lpage>. <pub-id pub-id-type="doi">10.1007/s12035-017-0632-1</pub-id>
<pub-id pub-id-type="pmid">28612257</pub-id></mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostov</surname><given-names>R. V.</given-names></name><name><surname>Knatko</surname><given-names>E. V.</given-names></name><name><surname>McLaughlin</surname><given-names>L. A.</given-names></name><name><surname>Henderson</surname><given-names>C. J.</given-names></name><name><surname>Zheng</surname><given-names>S.</given-names></name><name><surname>Huang</surname><given-names>J. T.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Pharmacokinetics and pharmacodynamics of orally administered acetylenic tricyclic bis(cyanoenone), a highly potent Nrf2 activator with a reversible covalent mode of action.</article-title>
<source/><italic>Biochem. Biophys. Res. Commun.</italic>
<volume>465</volume>
<fpage>402</fpage>–<lpage>407</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2015.08.016</pub-id>
<pub-id pub-id-type="pmid">26265043</pub-id></mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>V.</given-names></name><name><surname>Nestler</surname><given-names>E. J.</given-names></name></person-group> (<year>2008</year>). <article-title>The molecular neurobiology of depression.</article-title>
<source/><italic>Nature</italic>
<volume>455</volume>
<fpage>894</fpage>–<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1038/nature07455</pub-id>
<pub-id pub-id-type="pmid">18923511</pub-id></mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>M. K.</given-names></name><name><surname>Kensler</surname><given-names>T. W.</given-names></name></person-group> (<year>2010</year>). <article-title>Targeting NRF2 signaling for cancer chemoprevention.</article-title>
<source/><italic>Toxicol. Appl. Pharmacol.</italic>
<volume>244</volume>
<fpage>66</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2009.08.028</pub-id>
<pub-id pub-id-type="pmid">19732782</pub-id></mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>J. S.</given-names></name><name><surname>Hiles</surname><given-names>S.</given-names></name><name><surname>Bisquera</surname><given-names>A.</given-names></name><name><surname>Hure</surname><given-names>A. J.</given-names></name><name><surname>McEvoy</surname><given-names>M.</given-names></name><name><surname>Attia</surname><given-names>J.</given-names></name></person-group> (<year>2014</year>). <article-title>A systematic review and meta-analysis of dietary patterns and depression in community-dwelling adults.</article-title>
<source/><italic>Am. J. Clin. Nutr.</italic>
<volume>99</volume>
<fpage>181</fpage>–<lpage>197</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.113.069880</pub-id>
<pub-id pub-id-type="pmid">24196402</pub-id></mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Fang</surname><given-names>X.</given-names></name><name><surname>Zhan</surname><given-names>G.</given-names></name><name><surname>Huang</surname><given-names>N.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Role of Keap1-Nrf2 signaling in anhedonia symptoms in a rat model of chronic neuropathic pain: improvement with sulforaphane.</article-title>
<source/><italic>Front. Pharmacol.</italic>
<volume>9</volume>:<issue>887</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2018.00887</pub-id>
<pub-id pub-id-type="pmid">30135655</pub-id></mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>P. Y.</given-names></name><name><surname>Chang</surname><given-names>C. H.</given-names></name><name><surname>Chong</surname><given-names>M. F.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>K. P.</given-names></name></person-group> (<year>2017</year>). <article-title>Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>82</volume>
<fpage>560</fpage>–<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2017.02.1182</pub-id>
<pub-id pub-id-type="pmid">28410627</pub-id></mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>P. Y.</given-names></name><name><surname>Huang</surname><given-names>S. Y.</given-names></name><name><surname>Su</surname><given-names>K. P.</given-names></name></person-group> (<year>2010</year>). <article-title>A meta-analytic review of polyunsaturated fatty acid compositions in patients with depression.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>68</volume>
<fpage>140</fpage>–<lpage>147</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2010.03.018</pub-id>
<pub-id pub-id-type="pmid">20452573</pub-id></mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group> (<year>2016</year>). <article-title>Fruit and vegetable consumption and the risk of depression: a meta-analysis.</article-title>
<source/><italic>Nutrition</italic>
<volume>32</volume>
<fpage>296</fpage>–<lpage>302</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2015.09.009</pub-id>
<pub-id pub-id-type="pmid">26691768</pub-id></mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>X. H.</given-names></name><name><surname>Dwyer</surname><given-names>D. S.</given-names></name></person-group> (<year>2005</year>). <article-title>Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways.</article-title>
<source/><italic>J. Mol. Neurosci.</italic>
<volume>27</volume>
<fpage>43</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1385/JMN:27:1:043</pub-id>
<pub-id pub-id-type="pmid">16055946</pub-id></mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lukic</surname><given-names>I.</given-names></name><name><surname>Mitic</surname><given-names>M.</given-names></name><name><surname>Djordjevic</surname><given-names>J.</given-names></name><name><surname>Tatalovic</surname><given-names>N.</given-names></name><name><surname>Bozovic</surname><given-names>N.</given-names></name><name><surname>Soldatovic</surname><given-names>I.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients.</article-title>
<source/><italic>Neuropsychology</italic>
<volume>70</volume>
<fpage>1</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1159/000362841</pub-id>
<pub-id pub-id-type="pmid">25170744</pub-id></mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>R.</given-names></name><name><surname>Diggins</surname><given-names>E. L.</given-names></name><name><surname>Connors</surname><given-names>S. L.</given-names></name><name><surname>Zimmerman</surname><given-names>A. W.</given-names></name><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Liu</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Sulforaphane from broccoli reduces symptoms of autism: a follow-up case series from a randomized double-blind study.</article-title>
<source/><italic>Glob. Adv. Health Med.</italic>
<volume>6</volume>:<issue>21644957X17735826</issue>. <pub-id pub-id-type="doi">10.1177/2164957X17735826</pub-id>
<pub-id pub-id-type="pmid">29147630</pub-id></mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q.</given-names></name></person-group> (<year>2013</year>). <article-title>Role of Nrf2 in oxidative stress and toxicity.</article-title>
<source/><italic>Annu. Rev. Pharmacol. Toxicol.</italic>
<volume>53</volume>
<fpage>401</fpage>–<lpage>426</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-pharmtox-011112-140320</pub-id>
<pub-id pub-id-type="pmid">23294312</pub-id></mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martín-de-Saavedra</surname><given-names>M. D.</given-names></name><name><surname>Budni</surname><given-names>J.</given-names></name><name><surname>Cunha</surname><given-names>M. P.</given-names></name><name><surname>Gómez-Rangel</surname><given-names>V.</given-names></name><name><surname>Lorrio</surname><given-names>S.</given-names></name><name><surname>Del Barrio</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2013</year>). <article-title>Nrf2 participates in depressive disorders through an anti-inflammatory mechanism.</article-title>
<source/><italic>Psychoneuroendocrinology</italic>
<volume>38</volume>
<fpage>2010</fpage>–<lpage>2022</lpage>. <pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.03.020</pub-id>
<pub-id pub-id-type="pmid">23623252</pub-id></mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martín-Hernández</surname><given-names>D.</given-names></name><name><surname>Caso</surname><given-names>J. R.</given-names></name><name><surname>Javier Meana</surname><given-names>J.</given-names></name><name><surname>Callado</surname><given-names>L. F.</given-names></name><name><surname>Madrigal</surname><given-names>J. L. M.</given-names></name><name><surname>García-Bueno</surname><given-names>B.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Intracellular inflammatory and antioxidant pathways in postmortem frontal cortex of subjects with major depression: effect of antidepressants.</article-title>
<source/><italic>J. Neuroinflammation</italic>
<volume>15</volume>:<issue>251</issue>. <pub-id pub-id-type="doi">10.1186/s12974-018-1294-2</pub-id>
<pub-id pub-id-type="pmid">30180869</pub-id></mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marzec</surname><given-names>J. M.</given-names></name><name><surname>Christie</surname><given-names>J. D.</given-names></name><name><surname>Reddy</surname><given-names>S. P.</given-names></name><name><surname>Jedlicka</surname><given-names>A. E.</given-names></name><name><surname>Vuong</surname><given-names>H.</given-names></name><name><surname>Lanken</surname><given-names>P. N.</given-names></name><etal></etal></person-group> (<year>2007</year>). <article-title>Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury.</article-title>
<source/><italic>FASEB J.</italic>
<volume>21</volume>
<fpage>2237</fpage>–<lpage>2246</lpage>. <pub-id pub-id-type="doi">10.1096/fj.06-7759com</pub-id>
<pub-id pub-id-type="pmid">17384144</pub-id></mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuura</surname><given-names>A.</given-names></name><name><surname>Ishima</surname><given-names>T.</given-names></name><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Iwayama</surname><given-names>Y.</given-names></name><name><surname>Hasegawa</surname><given-names>S.</given-names></name><name><surname>Kawahara-Miki</surname><given-names>R.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Dietary glucoraphanin prevents the onset of psychosis in the adult offspring after maternal immune activation.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>8</volume>:<issue>2158</issue>. <pub-id pub-id-type="doi">10.1038/s41598-018-20538-3</pub-id>
<pub-id pub-id-type="pmid">29391571</pub-id></mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCullumsmith</surname><given-names>R. E.</given-names></name><name><surname>Hammond</surname><given-names>J. H.</given-names></name><name><surname>Shan</surname><given-names>D.</given-names></name><name><surname>Meador-Woodruff</surname><given-names>J. H.</given-names></name></person-group> (<year>2013</year>). <article-title>Postmortem brain: an underutilized substrate for studying severe mental illness.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>39</volume>
<fpage>65</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2013.239</pub-id>
<pub-id pub-id-type="pmid">24091486</pub-id></mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mechawar</surname><given-names>N.</given-names></name><name><surname>Savitz</surname><given-names>J.</given-names></name></person-group> (<year>2016</year>). <article-title>Neuropathology of mood disorders: do we see the stigmata of inflammation?</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>6</volume>:<issue>e946</issue>. <pub-id pub-id-type="doi">10.1038/tp.2016.212</pub-id>
<pub-id pub-id-type="pmid">27824355</pub-id></mixed-citation>
</ref>
<ref id="B50">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mello</surname><given-names>A. H.</given-names></name><name><surname>Gassenferth</surname><given-names>A.</given-names></name><name><surname>Souza</surname><given-names>L. R.</given-names></name><name><surname>Fortunato</surname><given-names>J. J.</given-names></name><name><surname>Rezin</surname><given-names>G. T.</given-names></name></person-group> (<year>2014</year>). <article-title>ω-3 and major depression: a review.</article-title>
<source/><italic>Acta Neuropsychiatr.</italic>
<volume>26</volume>
<fpage>178</fpage>–<lpage>185</lpage>. <pub-id pub-id-type="doi">10.1017/neu.2013.52</pub-id>
<pub-id pub-id-type="pmid">25142194</pub-id></mixed-citation>
</ref>
<ref id="B51">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mellon</surname><given-names>S. H.</given-names></name><name><surname>Wolkowitz</surname><given-names>O. M.</given-names></name><name><surname>Schonemann</surname><given-names>M. D.</given-names></name><name><surname>Epel</surname><given-names>E. S.</given-names></name><name><surname>Rosser</surname><given-names>R.</given-names></name><name><surname>Burke</surname><given-names>H. B.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Alterations in leukocyte transcriptional control pathway activity associated with major depressive disorder and antidepressant treatment.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>6</volume>:<issue>e821</issue>. <pub-id pub-id-type="doi">10.1038/tp.2016.79</pub-id>
<pub-id pub-id-type="pmid">27219347</pub-id></mixed-citation>
</ref>
<ref id="B52">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez-David</surname><given-names>I.</given-names></name><name><surname>Tritschler</surname><given-names>L.</given-names></name><name><surname>Ali</surname><given-names>Z. E.</given-names></name><name><surname>Damiens</surname><given-names>M. H.</given-names></name><name><surname>Pallardy</surname><given-names>M.</given-names></name><name><surname>David</surname><given-names>D. J.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Nrf2-signaling and BDNF: a new target for the antidepressant-like activity of chronic fluoxetine treatment in a mouse model of anxiety/depression.</article-title>
<source/><italic>Neurosci. Lett.</italic>
<volume>597</volume>
<fpage>121</fpage>–<lpage>126</lpage>. <pub-id pub-id-type="doi">10.1016/j.neulet.2015.04.036</pub-id>
<pub-id pub-id-type="pmid">25916883</pub-id></mixed-citation>
</ref>
<ref id="B53">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A. H.</given-names></name><name><surname>Haroon</surname><given-names>E.</given-names></name><name><surname>Felger</surname><given-names>J. C.</given-names></name></person-group> (<year>2017</year>). <article-title>Therapeutic implications of brain-immune interactions: treatment in translation.</article-title>
<source/><italic>Neuropsychopharmacology</italic>
<volume>42</volume>
<fpage>334</fpage>–<lpage>359</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2016.167</pub-id>
<pub-id pub-id-type="pmid">27555382</pub-id></mixed-citation>
</ref>
<ref id="B54">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A. H.</given-names></name><name><surname>Maletic</surname><given-names>V.</given-names></name><name><surname>Raison</surname><given-names>C. L.</given-names></name></person-group> (<year>2009</year>). <article-title>Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>65</volume>
<fpage>732</fpage>–<lpage>741</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2008.11.029</pub-id>
<pub-id pub-id-type="pmid">19150053</pub-id></mixed-citation>
</ref>
<ref id="B55">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>A. H.</given-names></name><name><surname>Raison</surname><given-names>C. L.</given-names></name></person-group> (<year>2016</year>). <article-title>The role of inflammation in depression: from evolutionary imperative to modern treatment target.</article-title>
<source/><italic>Nat. Rev. Immunol.</italic>
<volume>16</volume>
<fpage>22</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2015.5</pub-id>
<pub-id pub-id-type="pmid">26711676</pub-id></mixed-citation>
</ref>
<ref id="B56">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mills</surname><given-names>E. A.</given-names></name><name><surname>Ogrodnik</surname><given-names>M. A.</given-names></name><name><surname>Plave</surname><given-names>A.</given-names></name><name><surname>Mao-Draayer</surname><given-names>Y.</given-names></name></person-group> (<year>2018</year>). <article-title>Emerging understanding of the mechanism of action for dimethyl fumarate in the treatment of multiple sclerosis.</article-title>
<source/><italic>Front. Neurol.</italic>
<volume>9</volume>:<issue>5</issue>. <pub-id pub-id-type="doi">10.3389/fneur.2018.00005</pub-id>
<pub-id pub-id-type="pmid">29410647</pub-id></mixed-citation>
</ref>
<ref id="B57">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K.</given-names></name><name><surname>Sasaki</surname><given-names>S.</given-names></name></person-group> (<year>2010</year>). <article-title>Dietary intake and depressive symptoms: a systemic review of observational studies.</article-title>
<source/><italic>Mol. Nutr. Food. Res.</italic>
<volume>54</volume>
<fpage>471</fpage>–<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.200900157</pub-id>
<pub-id pub-id-type="pmid">19998381</pub-id></mixed-citation>
</ref>
<ref id="B58">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestler</surname><given-names>E. J.</given-names></name><name><surname>Barrot</surname><given-names>M.</given-names></name><name><surname>DiLeone</surname><given-names>R. J.</given-names></name><name><surname>Eisch</surname><given-names>A. J.</given-names></name><name><surname>Gold</surname><given-names>S. J.</given-names></name><name><surname>Monteggia</surname><given-names>L. M.</given-names></name></person-group> (<year>2002</year>). <article-title>Neurobiology of depression.</article-title>
<source/><italic>Neuron</italic>
<volume>34</volume>
<fpage>13</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/S0896-6273(02)00653-0</pub-id><pub-id pub-id-type="pmid">11931738</pub-id></mixed-citation>
</ref>
<ref id="B59">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nestler</surname><given-names>E. J.</given-names></name><name><surname>Hyman</surname><given-names>S. E.</given-names></name></person-group> (<year>2010</year>). <article-title>Animal models of neuropsychiatric disorders.</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>13</volume>
<fpage>1161</fpage>–<lpage>1169</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2647</pub-id>
<pub-id pub-id-type="pmid">20877280</pub-id></mixed-citation>
</ref>
<ref id="B60">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connell</surname><given-names>M. A.</given-names></name><name><surname>Hayes</surname><given-names>J. D.</given-names></name></person-group> (<year>2015</year>). <article-title>The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic.</article-title>
<source/><italic>Biochem. Soc. Trans.</italic>
<volume>43</volume>
<fpage>687</fpage>–<lpage>689</lpage>. <pub-id pub-id-type="doi">10.1042/BST20150069</pub-id>
<pub-id pub-id-type="pmid">26551713</pub-id></mixed-citation>
</ref>
<ref id="B61">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>J. C.</given-names></name><name><surname>Lawson</surname><given-names>M. A.</given-names></name><name><surname>André</surname><given-names>C.</given-names></name><name><surname>Moreau</surname><given-names>M.</given-names></name><name><surname>Lestage</surname><given-names>J.</given-names></name><name><surname>Castanon</surname><given-names>N.</given-names></name><etal></etal></person-group> (<year>2009</year>). <article-title>Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>14</volume>
<fpage>511</fpage>–<lpage>522</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4002148</pub-id>
<pub-id pub-id-type="pmid">18195714</pub-id></mixed-citation>
</ref>
<ref id="B62">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>R. M.</given-names></name><name><surname>Cryan</surname><given-names>J. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Adolescent brain vulnerability and psychopathology through the generations: role of diet and dopamine.</article-title>
<source/><italic>Biol. Psychiatry</italic>
<volume>75</volume>
<fpage>4</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2013.10.022</pub-id>
<pub-id pub-id-type="pmid">24314061</pub-id></mixed-citation>
</ref>
<ref id="B63">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohgi</surname><given-names>Y.</given-names></name><name><surname>Futamura</surname><given-names>T.</given-names></name><name><surname>Kikuchi</surname><given-names>T.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2013</year>). <article-title>Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>103</volume>
<fpage>853</fpage>–<lpage>859</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2012.12.003</pub-id>
<pub-id pub-id-type="pmid">23262300</pub-id></mixed-citation>
</ref>
<ref id="B64">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opie</surname><given-names>A.</given-names></name><name><surname>O’Neil</surname><given-names>R. S.</given-names></name><name><surname>Itsiopoulos</surname><given-names>C.</given-names></name><name><surname>Jacka</surname><given-names>F. N.</given-names></name></person-group> (<year>2015</year>). <article-title>The impact of whole-of-diet interventions on depression and anxiety: a systematic review of randomised controlled trials.</article-title>
<source/><italic>Public Health Nutr.</italic>
<volume>18</volume>
<fpage>2074</fpage>–<lpage>2093</lpage>. <pub-id pub-id-type="doi">10.1017/S1368980014002614</pub-id>
<pub-id pub-id-type="pmid">25465596</pub-id></mixed-citation>
</ref>
<ref id="B65">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paus</surname><given-names>T.</given-names></name><name><surname>Keshavan</surname><given-names>M.</given-names></name><name><surname>Giedd</surname><given-names>J. N.</given-names></name></person-group> (<year>2008</year>). <article-title>Why do many psychiatric disorders emerge during adolescence?</article-title>
<source/><italic>Nat. Rev. Neurosci.</italic>
<volume>9</volume>
<fpage>947</fpage>–<lpage>957</lpage>. <pub-id pub-id-type="doi">10.1038/nrn2513</pub-id>
<pub-id pub-id-type="pmid">19002191</pub-id></mixed-citation>
</ref>
<ref id="B66">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pergola</surname><given-names>P. E.</given-names></name><name><surname>Raskin</surname><given-names>P.</given-names></name><name><surname>Toto</surname><given-names>R. D.</given-names></name><name><surname>Meyer</surname><given-names>C. J.</given-names></name><name><surname>Huff</surname><given-names>J. W.</given-names></name><name><surname>Grossman</surname><given-names>E. B.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Bardoxolone methyl and kidney function in CKD with type 2 diabetes.</article-title>
<source/><italic>N. Eng. J. Med.</italic>
<volume>365</volume>
<fpage>327</fpage>–<lpage>336</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1105351</pub-id>
<pub-id pub-id-type="pmid">21699484</pub-id></mixed-citation>
</ref>
<ref id="B67">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raison</surname><given-names>C. L.</given-names></name><name><surname>Lowry</surname><given-names>C. A.</given-names></name><name><surname>Rook</surname><given-names>G. A.</given-names></name></person-group> (<year>2010</year>). <article-title>Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression.</article-title>
<source/><italic>Arch. Gen. Psychiatry</italic>
<volume>67</volume>
<fpage>1211</fpage>–<lpage>1224</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.161</pub-id>
<pub-id pub-id-type="pmid">21135322</pub-id></mixed-citation>
</ref>
<ref id="B68">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D.</given-names></name><name><surname>Villeneuve</surname><given-names>N. F.</given-names></name><name><surname>Jiang</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>T.</given-names></name><name><surname>Lau</surname><given-names>A.</given-names></name><name><surname>Toppin</surname><given-names>H. A.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>108</volume>
<fpage>1433</fpage>–<lpage>1438</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1014275108</pub-id>
<pub-id pub-id-type="pmid">21205897</pub-id></mixed-citation>
</ref>
<ref id="B69">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saghafian</surname><given-names>F.</given-names></name><name><surname>Malmir</surname><given-names>H.</given-names></name><name><surname>Saneei</surname><given-names>P.</given-names></name><name><surname>Milajerdi</surname><given-names>A.</given-names></name><name><surname>Larijani</surname><given-names>B.</given-names></name><name><surname>Esmaillzadeh</surname><given-names>A.</given-names></name></person-group> (<year>2018</year>). <article-title>Fruit and vegetable consumption and risk of depression: accumulative evidence from an updated systematic review and meta-analysis of epidemiological studies.</article-title>
<source/><italic>Br. J. Nutr.</italic>
<volume>119</volume>
<fpage>1087</fpage>–<lpage>1101</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114518000697</pub-id>
<pub-id pub-id-type="pmid">29759102</pub-id></mixed-citation>
</ref>
<ref id="B70">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarris</surname><given-names>J.</given-names></name><name><surname>Logan</surname><given-names>A. C.</given-names></name><name><surname>Akbaraly</surname><given-names>T. N.</given-names></name><name><surname>Amminger</surname><given-names>G. P.</given-names></name><name><surname>Balanzá-Martínez</surname><given-names>V.</given-names></name><name><surname>Freeman</surname><given-names>M. P.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Nutritional medicine as mainstream in psychiatry.</article-title>
<source/><italic>Lancet Psychiatry</italic>
<volume>2</volume>
<fpage>271</fpage>–<lpage>274</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(14)00051-0</pub-id><pub-id pub-id-type="pmid">26359904</pub-id></mixed-citation>
</ref>
<ref id="B71">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sedlak</surname><given-names>T. W.</given-names></name><name><surname>Nucifora</surname><given-names>L. G.</given-names></name><name><surname>Koga</surname><given-names>M.</given-names></name><name><surname>Shaffer</surname><given-names>L. S.</given-names></name><name><surname>Higgs</surname><given-names>C.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study.</article-title>
<source/><italic>Mol. Neuropsychiatry</italic>
<volume>3</volume>
<fpage>314</fpage>–<lpage>222</lpage>. <pub-id pub-id-type="doi">10.1159/000487639</pub-id>
<pub-id pub-id-type="pmid">29888232</pub-id></mixed-citation>
</ref>
<ref id="B72">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shelton</surname><given-names>R. C.</given-names></name><name><surname>Claiborne</surname><given-names>J.</given-names></name><name><surname>Sidoryk-Wegrzynowicz</surname><given-names>M.</given-names></name><name><surname>Reddy</surname><given-names>R.</given-names></name><name><surname>Aschner</surname><given-names>M.</given-names></name><name><surname>Lewis</surname><given-names>D. A.</given-names></name><etal></etal></person-group> (<year>2011</year>). <article-title>Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression.</article-title>
<source/><italic>Mol. Psychiatry</italic>
<volume>16</volume>
<fpage>751</fpage>–<lpage>762</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2010.52</pub-id>
<pub-id pub-id-type="pmid">20479761</pub-id></mixed-citation>
</ref>
<ref id="B73">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiina</surname><given-names>A.</given-names></name><name><surname>Kanahara</surname><given-names>N.</given-names></name><name><surname>Sasaki</surname><given-names>H.</given-names></name><name><surname>Oda</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Hasegawa</surname><given-names>T.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia.</article-title>
<source/><italic>Clin. Psychopharmacol. Neurosci.</italic>
<volume>13</volume>
<fpage>62</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2015.13.1.62</pub-id>
<pub-id pub-id-type="pmid">25912539</pub-id></mixed-citation>
</ref>
<ref id="B74">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirai</surname><given-names>Y.</given-names></name><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>R.</given-names></name><name><surname>Ohi</surname><given-names>K.</given-names></name><name><surname>Yamamori</surname><given-names>H.</given-names></name><name><surname>Yasuda</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood.</article-title>
<source/><italic>PLoS One</italic>
<volume>10</volume>:<issue>e0127244</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0127244</pub-id>
<pub-id pub-id-type="pmid">26107664</pub-id></mixed-citation>
</ref>
<ref id="B75">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Venkannagari</surname><given-names>S.</given-names></name><name><surname>Oh</surname><given-names>K. H.</given-names></name><name><surname>Zhang</surname><given-names>Y. Q.</given-names></name><name><surname>Rohde</surname><given-names>J. M.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Small molecule inhibitor of NRF2 selectively intervenes therapeutic resistance in KEAP1-deficient NSCLC tumors.</article-title>
<source/><italic>ACS Chem. Biol.</italic>
<volume>11</volume>
<fpage>3214</fpage>–<lpage>3225</lpage>. <pub-id pub-id-type="doi">10.1021/acschembio.6b00651</pub-id>
<pub-id pub-id-type="pmid">27552339</pub-id></mixed-citation>
</ref>
<ref id="B76">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>K.</given-names></name><name><surname>Connors</surname><given-names>S. L.</given-names></name><name><surname>Macklin</surname><given-names>E. A.</given-names></name><name><surname>Smith</surname><given-names>K. D.</given-names></name><name><surname>Fahey</surname><given-names>J. W.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Sulforaphane treatment of autism spectrum disorder (ASD).</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>111</volume>
<fpage>15550</fpage>–<lpage>15555</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1416940111</pub-id>
<pub-id pub-id-type="pmid">25313065</pub-id></mixed-citation>
</ref>
<ref id="B77">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Motohashi</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group> (<year>2013a</year>). <article-title>Toward clinical application of the Keap1-Nrf2 pathway.</article-title>
<source/><italic>Trends Pharmacol. Sci.</italic>
<volume>34</volume>
<fpage>340</fpage>–<lpage>346</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2013.04.005</pub-id>
<pub-id pub-id-type="pmid">23664668</pub-id></mixed-citation>
</ref>
<ref id="B78">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Shibata</surname><given-names>T.</given-names></name><name><surname>Takaya</surname><given-names>K.</given-names></name><name><surname>Shiraishi</surname><given-names>K.</given-names></name><name><surname>Kohno</surname><given-names>T.</given-names></name><name><surname>Kunitoh</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2013b</year>). <article-title>Regulatory nexus of synthesis and degradation deciphers cellular Nrf2 expression levels.</article-title>
<source/><italic>Mol. Cell. Biol.</italic>
<volume>33</volume>
<fpage>2402</fpage>–<lpage>2412</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.00065-13</pub-id>
<pub-id pub-id-type="pmid">23572560</pub-id></mixed-citation>
</ref>
<ref id="B79">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name></person-group> (<year>2015</year>). <article-title>Molecular basis of the Keap1-Nrf2 system.</article-title>
<source/><italic>Free Radic. Biol. Med.</italic>
<volume>88</volume>
<fpage>93</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2015.06.006</pub-id>
<pub-id pub-id-type="pmid">26117331</pub-id></mixed-citation>
</ref>
<ref id="B80">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuchida</surname><given-names>K.</given-names></name><name><surname>Tsujita</surname><given-names>T.</given-names></name><name><surname>Hayashi</surname><given-names>M.</given-names></name><name><surname>Ojima</surname><given-names>A.</given-names></name><name><surname>Keleku-Lukwete</surname><given-names>N.</given-names></name><name><surname>Katsuoka</surname><given-names>F.</given-names></name><etal></etal></person-group> (<year>2017</year>). <article-title>Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation.</article-title>
<source/><italic>Free Radic. Biol. Med.</italic>
<volume>103</volume>
<fpage>236</fpage>–<lpage>247</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2016.12.041</pub-id>
<pub-id pub-id-type="pmid">28039084</pub-id></mixed-citation>
</ref>
<ref id="B81">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name><name><surname>Niu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name></person-group> (<year>2018</year>). <article-title>Recent advances in nutrition for the treatment of depressive disorder.</article-title>
<source/><italic>Curr. Pharm. Des.</italic>
<pub-id pub-id-type="doi">10.2174/1381612824666180803113106</pub-id> [Epub ahead of print]. <pub-id pub-id-type="pmid">30073920</pub-id></mixed-citation>
</ref>
<ref id="B82">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y. Y.</given-names></name><name><surname>Yang</surname><given-names>Y. X.</given-names></name><name><surname>Zhe</surname><given-names>H.</given-names></name><name><surname>He</surname><given-names>Z. X.</given-names></name><name><surname>Zhou</surname><given-names>S. F.</given-names></name></person-group> (<year>2014</year>). <article-title>Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties.</article-title>
<source/><italic>Drug Des. Devel. Ther.</italic>
<volume>8</volume>
<fpage>2075</fpage>–<lpage>2088</lpage>. <pub-id pub-id-type="doi">10.2147/DDDT.S68872</pub-id>
<pub-id pub-id-type="pmid">25364233</pub-id></mixed-citation>
</ref>
<ref id="B83">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardyn</surname><given-names>J. D.</given-names></name><name><surname>Ponsford</surname><given-names>A. H.</given-names></name><name><surname>Sanderson</surname><given-names>C. M.</given-names></name></person-group> (<year>2015</year>). <article-title>Dissecting molecular cross-talk between Nrf2 and NF-κB response pathways.</article-title>
<source/><italic>Biochem. Soc. Trans.</italic>
<volume>43</volume>
<fpage>621</fpage>–<lpage>626</lpage>. <pub-id pub-id-type="doi">10.1042/BST20150014</pub-id>
<pub-id pub-id-type="pmid">26551702</pub-id></mixed-citation>
</ref>
<ref id="B84">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B.</given-names></name><name><surname>Dwyer</surname><given-names>D. S.</given-names></name></person-group> (<year>2009</year>). <article-title>Structure-based discovery of low molecular weight compounds that stimulate neurite outgrowth and substitute for nerve growth factor.</article-title>
<source/><italic>J. Neurochem.</italic>
<volume>110</volume>
<fpage>1876</fpage>–<lpage>1884</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2009.06291.x</pub-id>
<pub-id pub-id-type="pmid">19627449</pub-id></mixed-citation>
</ref>
<ref id="B85">
<mixed-citation publication-type="journal"><collab>World Health Organization [WHO]</collab> (<year>2017</year>). <source/><italic>Depression.</italic> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/en/news-room/fact-sheets/detail/depression">http://www.who.int/en/news-room/fact-sheets/detail/depression</ext-link></mixed-citation>
</ref>
<ref id="B86">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Kensler</surname><given-names>T. W.</given-names></name><name><surname>Motohashi</surname><given-names>H.</given-names></name></person-group> (<year>2018</year>). <article-title>The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeostasis.</article-title>
<source/><italic>Physiol. Rev.</italic>
<volume>98</volume>
<fpage>1169</fpage>–<lpage>1203</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00023.2017</pub-id>
<pub-id pub-id-type="pmid">29717933</pub-id></mixed-citation>
</ref>
<ref id="B87">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Kyo</surname><given-names>M.</given-names></name><name><surname>Kamiya</surname><given-names>T.</given-names></name><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Engel</surname><given-names>J. D.</given-names></name><name><surname>Motohashi</surname><given-names>H.</given-names></name><etal></etal></person-group> (<year>2006</year>). <article-title>Predictive base substitution rules that determine the binding and transcriptional specificity of Maf recognition elements.</article-title>
<source/><italic>Genes Cells</italic>
<volume>11</volume>
<fpage>575</fpage>–<lpage>591</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2443.2006.00965.x</pub-id>
<pub-id pub-id-type="pmid">16716189</pub-id></mixed-citation>
</ref>
<ref id="B88">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Chen</surname><given-names>Q. X.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2017</year>). <article-title>Altered expression of BDNF, BDNF pro-peptide and their precursor proBDNF in brain and liver tissues from psychiatric disorders: rethinking the brain-liver axis.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>7</volume>:<issue>e1128</issue>. <pub-id pub-id-type="doi">10.1038/tp.2017.95</pub-id>
<pub-id pub-id-type="pmid">28509900</pub-id></mixed-citation>
</ref>
<ref id="B89">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Chen</surname><given-names>Q. X.</given-names></name><name><surname>Shirayama</surname><given-names>Y.</given-names></name><etal></etal></person-group> (<year>2016</year>). <article-title>Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, proBDNF and preproBDNF in the brain confer stress resilience.</article-title>
<source/><italic>Eur. Arch. Psychiatry Clin. Neurosci.</italic>
<volume>266</volume>
<fpage>765</fpage>–<lpage>769</lpage>. <pub-id pub-id-type="doi">10.1007/s00406-016-0693-6</pub-id>
<pub-id pub-id-type="pmid">27094192</pub-id></mixed-citation>
</ref>
<ref id="B90">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Rong</surname><given-names>J.</given-names></name></person-group> (<year>2015c</year>). <article-title>Releasing Nrf2 to promote neurite outgrowth.</article-title>
<source/><italic>Neural. Regen. Res.</italic>
<volume>10</volume>
<fpage>1934</fpage>–<lpage>1935</lpage>. <pub-id pub-id-type="doi">10.4103/1673-5374.169618</pub-id>
<pub-id pub-id-type="pmid">26889175</pub-id></mixed-citation>
</ref>
<ref id="B91">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Shirayama</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2015a</year>). <article-title>Peripheral interleukin-6 promotes resilience versus susceptibility to inescapable stress.</article-title>
<source/><italic>Acta Neuropsychiatr.</italic>
<volume>27</volume>
<fpage>312</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1017/neu.2015.36</pub-id>
<pub-id pub-id-type="pmid">26017899</pub-id></mixed-citation>
</ref>
<ref id="B92">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Shirayama</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2015b</year>). <article-title>Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress.</article-title>
<source/><italic>Int. J. Neuropsychopharmacol.</italic>
<volume>18</volume>:<issue>yu121</issue>. <pub-id pub-id-type="doi">10.1093/ijnp/pyu121</pub-id>
<pub-id pub-id-type="pmid">25568287</pub-id></mixed-citation>
</ref>
<ref id="B93">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>M.</given-names></name><name><surname>Dang</surname><given-names>R.</given-names></name><name><surname>Xu</surname><given-names>P.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>W.</given-names></name><name><surname>Liao</surname><given-names>D.</given-names></name><etal></etal></person-group> (<year>2018</year>). <article-title>Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>235</volume>
<fpage>2573</fpage>–<lpage>2585</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-018-4949-x</pub-id>
<pub-id pub-id-type="pmid">29943092</pub-id></mixed-citation>
</ref>
<ref id="B94">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Zhuang</surname><given-names>C.</given-names></name><name><surname>Hirota</surname><given-names>S.</given-names></name><name><surname>Inanaga</surname><given-names>K.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Effects of amycenone on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration.</article-title>
<source/><italic>Pharmacol. Biochem. Behav.</italic>
<volume>136</volume>
<fpage>7</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2015.06.012</pub-id>
<pub-id pub-id-type="pmid">26150007</pub-id></mixed-citation>
</ref>
<ref id="B95">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J. W.</given-names></name><name><surname>Ishima</surname><given-names>T.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2016a</year>). <article-title>Antidepressant effects of TBE-31 and MCE-1, the novel Nrf2 activators, in an inflammation model of depression.</article-title>
<source/><italic>Eur. J. Pharmacol.</italic>
<volume>793</volume>
<fpage>21</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2016.10.037</pub-id>
<pub-id pub-id-type="pmid">27815170</pub-id></mixed-citation>
</ref>
<ref id="B96">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>J. W.</given-names></name><name><surname>Ishima</surname><given-names>T.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><etal></etal></person-group> (<year>2016b</year>). <article-title>Role of Keap1-Nrf2 signaling in depression and dietary intake of glucoraphanin confers stress resilience in mice.</article-title>
<source/><italic>Sci. Rep.</italic>
<volume>6</volume>:<issue>30659</issue>. <pub-id pub-id-type="doi">10.1038/srep30659</pub-id>
<pub-id pub-id-type="pmid">27470577</pub-id></mixed-citation>
</ref>
<ref id="B97">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J. J.</given-names></name><name><surname>Bruno</surname><given-names>D.</given-names></name><name><surname>Pomara</surname><given-names>N.</given-names></name></person-group> (<year>2014</year>). <article-title>A review of the relationship between pro-inflammatory cytokines and major depressive disorder.</article-title>
<source/><italic>J. Affect. Disord.</italic>
<volume>169</volume>
<fpage>15</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2014.07.032</pub-id>
<pub-id pub-id-type="pmid">25128861</pub-id></mixed-citation>
</ref>
<ref id="B98">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>C.</given-names></name><name><surname>Pan</surname><given-names>S.</given-names></name><name><surname>Dong</surname><given-names>M.</given-names></name><name><surname>Niu</surname><given-names>Y.</given-names></name></person-group> (<year>2017</year>). <article-title>Astragaloside IV attenuates lead acetate-induced inhibition of neurite outgrowth through activation of Akt-dependent Nrf2 pathway in vitro.</article-title>
<source/><italic>Biochem. Biophys. Acta</italic>
<volume>1863</volume>
<fpage>1195</fpage>–<lpage>1203</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbadis.2017.03.006</pub-id>
<pub-id pub-id-type="pmid">28315454</pub-id></mixed-citation>
</ref>
<ref id="B99">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Fujita</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><etal></etal></person-group> (<year>2014</year>). <article-title>Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation.</article-title>
<source/><italic>Int. J. Neuropsychopharmacol.</italic>
<volume>18</volume>:<issue>yu077</issue>. <pub-id pub-id-type="doi">10.1093/ijnp/pyu077</pub-id>
<pub-id pub-id-type="pmid">25628381</pub-id></mixed-citation>
</ref>
<ref id="B100">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Shirayama</surname><given-names>Y.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2018</year>). <article-title>Keap1-Nrf2 signaling pathway confers resilience versus susceptibility to inescapable electric stress.</article-title>
<source/><italic>Eur. Arch. Psychiatry Clin. Neurosci.</italic>
<pub-id pub-id-type="doi">10.1007/s00406-017-0848-0</pub-id> [Epub ahead of print]. <pub-id pub-id-type="pmid">29119264</pub-id></mixed-citation>
</ref>
<ref id="B101">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017a</year>). <article-title>Blockade of interleukin-6 receptor in the periphery promotes rapid and sustained antidepressant actions: a possible role of gut-microbiota-brain axis.</article-title>
<source/><italic>Transl. Psychiatry</italic>
<volume>7</volume>:<issue>e1138</issue>. <pub-id pub-id-type="doi">10.1038/tp.2017.112</pub-id>
<pub-id pub-id-type="pmid">28556833</pub-id></mixed-citation>
</ref>
<ref id="B102">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2015</year>). <article-title>Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.</article-title>
<source/><italic>Psychopharmacology</italic>
<volume>232</volume>
<fpage>4325</fpage>–<lpage>4335</lpage>. <pub-id pub-id-type="doi">10.1007/s00213-015-4062-3</pub-id>
<pub-id pub-id-type="pmid">26337614</pub-id></mixed-citation>
</ref>
<ref id="B103">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Dong</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>C.</given-names></name><name><surname>Ren</surname><given-names>Q.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><etal></etal></person-group> (<year>2017b</year>). <article-title>Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation.</article-title>
<source/><italic>J. Nutr. Biochem.</italic>
<volume>39</volume>
<fpage>134</fpage>–<lpage>144</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2016.10.004</pub-id>
<pub-id pub-id-type="pmid">27833054</pub-id></mixed-citation>
</ref>
<ref id="B104">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J. C.</given-names></name><name><surname>Yao</surname><given-names>W.</given-names></name><name><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>Brain-derived neurotrophic factor (BDNF) – TrkB signaling in inflammation-related depression and potential therapeutic targets.</article-title>
<source/><italic>Curr. Neuropharmacol.</italic>
<volume>14</volume>
<fpage>721</fpage>–<lpage>731</lpage>. <pub-id pub-id-type="doi">10.2174/1570159X14666160119094646</pub-id><pub-id pub-id-type="pmid">26786147</pub-id></mixed-citation>
</ref>
<ref id="B105">
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Talalay</surname><given-names>P.</given-names></name><name><surname>Cho</surname><given-names>C. G.</given-names></name><name><surname>Posner</surname><given-names>G. H.</given-names></name></person-group> (<year>1992</year>). <article-title>A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure.</article-title>
<source/><italic>Proc. Natl. Acad. Sci. U.S.A.</italic>
<volume>89</volume>
<fpage>2399</fpage>–<lpage>2403</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.89.6.2399</pub-id>
<pub-id pub-id-type="pmid">1549603</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>